TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04667910
Drug: 601 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection (intravitreal use)
Study: NCT04667910
Drug: Ranibizuman 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection (intravitreal use)
Study: NCT02318537
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching oral solution containing no cannabidiol.
Study: NCT03012009
Drug: lidocaine hydrochloride 2% with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00621751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01269411
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00286481
Drug: Lapaquistat acetate and simvastatin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study: NCT00286481
Drug: Lapaquistat acetate and simvastatin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study: NCT00286481
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study: NCT00188565
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03170518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet will be administered orally once-daily.
Study: NCT02957929
Drug: APX001 single IV dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 single oral dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 single oral dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 single oral dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 single oral dose fasted
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 single oral dose fed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 multiple oral doses 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 multiple oral doses 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: APX001 multiple oral doses 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: Cytochrome P450 substrates
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02957929
Drug: Matching placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03918148
Drug: SGLT-2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
Study: NCT03918148
Drug: DPP-4i
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
Study: NCT04128085
Drug: TQB3804
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of tyrosine kinase inhibitor.
Study: NCT00134030
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04258241
Drug: Solution with local anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
Study: NCT00134030
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02187744
Drug: Taxotere®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study: NCT04258241
Drug: Solution without local anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
Study: NCT02187744
Drug: Paraplatin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study: NCT01972568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
Study: NCT01167309
Drug: LEO 27847
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First in patient
Study: NCT02289768
Drug: 5-fluorouracil/salicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289768
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03977584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
Study: NCT00306189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC every 6 months
Study: NCT02215174
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg po x1
Study: NCT04149990
Drug: Entresto Pill
Normalized name: Entresto Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO other interventions
Study: NCT06081712
Drug: TNP-2198 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Study: NCT02741856
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For more information please see the arm descriptions section.
Study: NCT04032782
Drug: HM15136
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL as protein in prefilled syringes
Study: NCT04032782
Drug: Placebo of HM15136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in prefilled syringes
Study: NCT00670501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
Study: NCT00670501
Drug: Calcium Supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
Study: NCT02865538
Drug: BAY3427080
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02865538
Drug: Placebo (for BAY3427080)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04678856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT02416570
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02416570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00929877
Drug: KETOPROFEN(RP19583)
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Study: NCT00929877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Study: NCT01518881
Drug: TKM-100201
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT01518881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01904786
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01904786
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00046709
Drug: Smoked Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04883736
Drug: Tretinoin Gel Microsphere, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT04883736
Drug: RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT04883736
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT04978025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Study: NCT01752270
Drug: Diane-35 pretreatment
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
Study: NCT01752270
Drug: Diane-35 pretreatment
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04520412
Drug: GV-971
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT04520412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT00630565
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
Study: NCT00768183
Drug: KADIAN Capsule + alcohol (under fasting conditions)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Study: NCT00768183
Drug: KADIAN Capsule + alcohol (under fed conditions)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Study: NCT03175978
Drug: IGF/MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
Study: NCT00981305
Drug: Lactate-containing vaginal lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Study: NCT00981305
Drug: Placebo vaginal lubricant
Normalized name: LUBRICANT,VAGINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Study: NCT00911547
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhaler taken twice daily for 16 weeks
Study: NCT00911547
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken once daily at bedtime for 16 weeks
Study: NCT03817502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, oral administration, once daily.
Study: NCT03363997
Drug: Estriol 0.125 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of one vaginal ring
Study: NCT03363997
Drug: Estriol 0.250 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of one vaginal ring
Study: NCT03363997
Drug: Estriol 0.500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of one vaginal ring
Study: NCT00076843
Drug: Hu MiK-Beta-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01590459
Drug: VX-509 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral tablet
Study: NCT03531931
Drug: Apatinib/Capecitatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
Study: NCT02432261
Drug: Nestorone® /testosterone gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone® /testosterone combined gel
Study: NCT02432261
Drug: Testosterone only gel
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone only gel
Study: NCT03945591
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV over 2 hours on Day +3 and +4
Study: NCT04600141
Drug: Heparin - Therapeutic dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
Study: NCT04600141
Drug: Heparin - Prophylactic dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
Study: NCT04209192
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Is the prophylactic drug which will be used in the control group.
Study: NCT00238550
Drug: Cannabis based medicine extract (CBME)
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01368536
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 15 mg and 25 mg capsule
Study: NCT01368536
Drug: Placebo of Valturna Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of valturna tablet
Study: NCT01368536
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
Study: NCT01621230
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
Study: NCT01264783
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60 for intravenous administration
Study: NCT04516148
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing per hospital policy
Study: NCT01264783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline for injection
Study: NCT03482713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (film-coated tablet) matching gefapixant to be administered orally BID
Study: NCT05432843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive a treatment with placebo for 8 weeks
Study: NCT00521456
Drug: ketorolac eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo
Study: NCT02242266
Drug: Spiriva® HandiHaler® high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium inhalation powder, hard gelatine capsule
Study: NCT02242266
Drug: Placebo via the blue HandiHaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhalation via the blue HandiHaler®
Study: NCT02242266
Drug: Placebo via the grey HandiHaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhalation via the grey HandiHaler®
Study: NCT00210184
Drug: Irinotecan associated to fluorouracil and leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03748108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
Study: NCT01241461
Drug: LY2584702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met.
Study: NCT04505436
Drug: Placebo of HM15211
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile, matching solution in pre-filled syringes
Study: NCT01489722
Drug: AZD1208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
Study: NCT00119613
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00302107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Look-a-like placebo tablets under double-blind conditions
Study: NCT00074269
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01790932
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014571
Drug: GSK2878175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
Study: NCT02014571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
Study: NCT00453063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sprays in each nostril once daily in the morning
Study: NCT04052334
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
Study: NCT01441180
Drug: GS7977
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug intervention
Study: NCT01457144
Drug: RiBVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2
Study: NCT02352883
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo endocrine therapy
Study: NCT04395365
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02637557
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
Study: NCT03069352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01625377
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation
Study: NCT01625377
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Study: NCT03451266
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
Study: NCT00808626
Drug: 99mTc-rBitistatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
Study: NCT02043366
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline is intravenously administrated before anesthesia induction
Study: NCT04381143
Drug: Aspirin 100 mg Oral Tablet
Normalized name: aspirin 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg tablet daily
Study: NCT04381143
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo 1 pill daily
Study: NCT02043366
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is intravenously administrated
Study: NCT02043366
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil is intravenously administrated
Study: NCT02718495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01504620
Drug: insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of insulin